MorphoSys Announces Clinical Milestone from Strategic Alliance

Second Clinical Milestone in 2010

05-Jul-2010 - Germany

MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. The news represents the second HuCAL-derived antibody to achieve this stage during the course of 2010, following a clinical milestone hit as part of the alliance with Centocor in June 2010.

"Therapeutic antibodies based on our technologies will be our main value driver in the years ahead and we expect our pipeline to continue to expand and mature. At the end of 2010, we expect MorphoSys to be participating in almost 80 unique product opportunities," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news represents the third antibody to enter clinical development from our collaboration with Novartis and the second HuCAL-derived antibody to enter clinical development this year."

MorphoSys projects that in 2010 between four and six partnered programs could enter clinical trials. With the recently announced in-licensing of an Fc-engineered antibody against CD19 from Xencor Inc., MorphoSys now expects up to 15 proprietary and partnered antibody programs to be in clinical trials including at least four programs in phase 2 clinical trials by year end.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous